Background Prostate cancer (PCa) is the most common male malignancy in the western world. Many men (40%) are diagnosed with localised low or intermediate-risk PCa, which is suitable for active ...
URO-1, Inc. is a life sciences company dedicated to advancing the tools and workflows used in soft tissue biopsy diagnostics.
Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results